Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05417971 · ClinicalTrials.gov registry record
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
A clinical trial of Hematologic Malignancy, sponsored by Northside Hospital.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT05417971: Recruiting study of Hematologic Malignancy, sponsored by Northside Hospital.
NCT05417971 is a study of Hematologic Malignancy that is actively recruiting participants, run by Northside Hospital. The registered enrollment target is 20 participants, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05417971, a study of Hematologic Malignancy, is actively recruiting participants, sponsored by Northside Hospital.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
Conditions Studied
Interventions
- OTHER Fludarabine
Study Locations (1)
Georgia
- Caitlin Guzowski - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2026-12-31 |
What NCT05417971 shows while recruiting
NCT05417971 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Fludarabine is the first listed.
NCT05417971 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05417971 about?
NCT05417971 is a clinical study titled "Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation". This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
What is the current status of trial NCT05417971?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2022-08-29. Estimated completion is 2026-12-31.
What conditions does trial NCT05417971 study?
This clinical trial studies the following conditions: Hematologic Malignancy.
What interventions are being tested in trial NCT05417971?
The interventions under investigation include: Fludarabine (OTHER).
Who is sponsoring clinical trial NCT05417971?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05417971 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05417971's enrollment target sits among peer trials
20 42nd of 48 higher than 4 of 48 other Hematologic Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
RECRUITING
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI